# Hatem Soliman

Source: https://onco.cc/people/hatem-soliman/  
OnCo record `hatem-soliman` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Hatem Soliman is a breast oncologist leading immunotherapy and genomic-assay trials, including in triple-negative disease.

## Summary

Hatem Soliman is Medical Director of the Clinical Trials Office and a breast oncologist at Moffitt Cancer Center. He is known for leading immunotherapy and genomic-assay trials in breast cancer, including in triple-negative disease, and for work validating breast genomic classifiers. His selected paper reports a phase 2 study of the IDO inhibitor indoximod with chemotherapy in metastatic breast cancer. He now runs Moffitt's clinical trials office and continues as an investigator in triple-negative and hormone receptor-positive breast cancer studies.

## Fields

- Kind: Person
- Last checked: 2026-09-08
- Role: Medical Director, Clinical Trials Office; Breast Oncology
- Specialisms: Breast cancer; Immunotherapy; Genomic assays

## Sources

- Moffitt profile: https://www.moffitt.org/providers/hatem-soliman/
- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Soliman%20H%5BAuthor%5D

## Connected records

- cancers: [HR-positive / HER2-negative breast cancer](https://onco.cc/cancers/breast-hr-positive/), [Triple-negative breast cancer (TNBC)](https://onco.cc/cancers/tnbc/)
- institutions: [Moffitt Cancer Center](https://onco.cc/institutions/moffitt/)
- journals: [Cancer Immunology Research](https://onco.cc/journals/cancer-immunology-research/)

---
JSON: https://onco.cc/api/v1/entities/hatem-soliman.json